Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer

Opinion
Video

Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
2 experts in this video
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content